XLO stock icon

Xilio Therapeutics


About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Employees: 73

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

44% more capital invested

Capital invested by funds: $8.22M [Q4 2023] → $11.9M (+$3.63M) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

9% less funds holding

Funds holding: 33 [Q4 2023] → 30 (-3) [Q1 2024]

14.36% less ownership

Funds ownership: 54.29% [Q4 2023] → 39.93% (-14.36%) [Q1 2024]

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Research analyst outlook

We haven’t received any recent analyst ratings for XLO.

Financial journalist opinion